BridgeMD
Nivolumab during active surveillance after neoadjuvant chemoradiation for esophageal cancer: SANO-3 study
EU CTIS ID: 2024-513635-24-00
What this study is testing
To assess the efficacy of nivolumab during active surveillance in patients with cCR after neoadjuvant chemoradiation for esophageal cancer
- Phase II and Phase III (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Operable patients with locoregionally advanced squamous cell- or adenocarcinoma of the esophagus or esophagogastric junction who have completed neoadjuvant chemoradiotherapy (nCRT) and have clinically complete reponse at 10-14 weeks after nCRT and are in an active surveillance protocol (SANO-2 study)
- Age ≥18
- Written, voluntary, informed consent
You likely can't join if
- Patients who were treated with definitive chemoradiotherapy
- Patients who were unable to complete all radiotherapy fractions
- Language difficulty, dementia or altered mental status prohibiting the understanding and giving of informed consent and to complete quality of life questionnaires
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.